Zarrabian Saiid 4
4 · DelMar Pharmaceuticals, Inc. · Filed Sep 9, 2019
Insider Transaction Report
Form 4
Zarrabian Saiid
DirectorInterim CEO
Transactions
- Award
Options (Right to Buy)
2019-09-05+241,438→ 241,438 totalExercise: $0.61Exp: 2029-09-05→ Common Stock (241,438 underlying) - Award
Options (Right to Buy)
2019-09-05+216,212→ 216,212 totalExercise: $0.61Exp: 2029-09-05→ Common Stock (216,212 underlying)
Footnotes (2)
- [F1]Subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the next annual meeting, 1/6th of the options vest on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020.
- [F2]1/6th of the options vest on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020.